References
- Alvarez-Jimenez, M., Hetrick, S., Gonzalez-Blanch, C., Gleeson, J., & McGorry, P. (2008). Non-pharmacological management of antipsychotic-induced weight-gain: Systematic review and meta-analysis of randomised controlled trials. British Journal of Psychiatry, 193, 101–107. doi: https://doi.org/10.1192/bjp.bp.107.042853
- American Psychiatric Association (APA). (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing
- Assion, H., Reinbold, H., Lemanski, S., Basilowski, M., & Juckel, G. (2008). Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine: A randomized, double-bine, placebo-controlled trial. Pharmacopsychiatry, 41, 24–28. doi: https://doi.org/10.1055/s-2007-993209
- Bano, M.D., Mico, J.A., Agujetas, M., Lopez, M.L., & Guillen, J.L. (2001). Olanzapine efficacy in the treatment of cocaine abuse in methadone maintenance patients. Interaction with plasma levels. Actas Espanolas De Psiquiatria, 29, 24–220
- Benyamina, A., Reynaud, M., Blecha, L., & Karila, L. (2011). Pharmacological treatments of opiate dependence. Current Pharmaceutical Design, 17, 1384–1388. doi: https://doi.org/10.2174/138161211796150855
- Berridge, V. (2012). The rise, fall, and revival of recovery in drug policy. The Lancet, 379, 22–23. doi: https://doi.org/10.1016/s0140-6736(12)60011-7
- Carra, G., Johnson, S., Bebbington, P., Angermeyer, M., Heider, D., Brugha, T., … Toumi, M. (2012). The lifetime and past-year prevalence of dual diagnosis in people with schizophrenia across Europe: Findings from the European Schizophrenia Cohort (EuroSC). European Archives of Psychiatry and Clinical Neuroscience, 262, 607–616. doi: https://doi.org/10.3410/f.717970688.793469240
- Chandler, A., Whittaker, A., Williams, N., McGorm, K., Cunningham-Burley, S., & Mathews, G. (2014). Mother’s little helper? Contrasting accounts of benzodiazepine and methadone use among drug-dependent parents in the UK. Drugs: Education, Prevention and Policy, 21, 470–475. doi: https://doi.org/10.3109/09687637.2014.930814
- Chassin, L., Collins, R., Ritter, J., Shirley, M., Zvolensky, M., & Kashdan, T. (2010). Vulnerability to substance use across the lifespan. In Ingram, R., & Price, J. (Eds.), Vulnerability to psychopathology: Risk across the lifespan (pp. 176–185). NYC: Guilford
- Chilton, J., Parrish, M., & Crone, D. (2011). A preliminary review of an outpatient dual diagnosis recovery group programme. Groupwork, 21, 78–91. doi: https://doi.org/10.1921/095182411x636554
- Compton, P., Charuvastra, V.C., & Ling, W. (2001). Pain intolerance in opioid-maintained former opiate addicts: Effect of long-acting maintenance agent. Drug and Alcohol Dependence, 63, 139–146. doi: https://doi.org/10.1016/s0376-8716(00)00200-3
- Crome, I.B. (1999). Substance misuse and psychiatric comorbidity: Towards improved service provision. Drugs: Education, Prevention and Policy, 6, 151–174. doi: https://doi.org/10.1080/09687639997115
- Crome, I.B. (2006). An epidemiological perspective of psychiatric comorbidity and substance misuse: The UK experience/example. In: Baldacchino, A., & Corkery, J. (Eds.), Comorbidity: Perspectives across Europe (ECCAS Monograph No. 4) (pp. 45–60). London: European Collaborating Centres in Addictive Studies (ECCAS)
- Crome, I., & Chambers, P. (2009). The relationship between dual diagnosis: Substance misuse and dealing with mental health issues. London: Social Care Institute for Excellence. Retrieved from http://www.scie.org.uk/publications/briefings/files/briefing30.pdf [Accessed 1st March 2014]
- de Wit, H. (2010). Amisulpride. In Stolerman, I.P. (Ed.), Encyclopedia of psychopharmacology (Vol. I, p. 77). London: Springer
- den Boon, F., Body, S., Hapson, C., Bradshaw, C., Szabadi, E., & de Bruin, N. (2012). Effects of amisulpride and aripiprazole on progressive-ratio schedule performance: Comparison with clozapine and haloperidol. Journal of Psychopharmacology, 26, 1231–1243. doi: https://doi.org/10.1177/0269881111421974
- Department of Health. (2007). Drug misuse and dependence. UK guidelines on clinical management. London: DoH
- Department of Health. (2006). Dual diagnosis in mental health inpatient and day hospital settings. Guidance on the assessment and management of patients in mental health inpatient and day hospital settings who have mental ill health and substance use problems. London: Department of Health
- Department of Health. (2002). Mental health policy implementation guide: Dual diagnosis good practice guide. London: Department of Health. Retrieved from: http://www.fenacerci.pt/web/publicacoes/outras/guia_dd.pdf [Accessed 17th April 2014]
- Dole, V., & Nyswander, M. (1967). Heroin addiction: A metabolic disease. Archives of Internal Medicine, 120, 19–24. doi: https://doi.org/10.1001/archinte.120.1.19
- Drake, R.E., Mueser, K.T., & Brunette, M.F. (2007). Management of persons with co-occurring severe mental illness and substance use disorder: Program implications. World Psychiatry, 6, 131–136
- Drake, R.E., Xie, H., McHugo, G.J., & Green, A.I. (2000). The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophrenia Bulletin, 26, 441–449. doi: https://doi.org/10.1093/oxfordjournals.schbul.a033464
- Engel, G. (1979). The biopsychosocial model and the education of health professionals. General Hospital Psychiatry, 1, 156–165. doi: https://doi.org/10.1016/0163-8343(79)90062-8
- Ereshefsky, L. (2009). Q&A: Drug-drug interactions with the use of psychotropic medications. Supplement to CNS Spectrums, 14, 1–8. Retrieved from: http://www.cnsspectrums.com/UserDocs/0809CNS Q A Ereshefsky.pdf
- Ferrari, A., Coccia, C.P.R., Bertolini, A., & Sternieri, E. (2004). Methadone—metabolism, pharmacokinetics and interactions. Pharmacological Research, 50, 551–559. doi: https://doi.org/10.1016/j.phrs.2004.05.002
- Forrester, D., & Harwin, J. (2011). Parents who misuse drugs and alcohol: Effective interventions in social work and child protection. Chichester: Wiley
- Frisher, M., Crome, I., Macleod, J., Milson, D., & Croft, P. (2005). Substance use and psychiatric illness: Prospective observational study using the General Practice Research Database. Journal of Epidemiology and Community Health, 59, 847–850. doi: https://doi.org/10.1136/jech.2004.030833
- Gardner, D.M., Baldessarini, R.J., & Waraich, P. (2005). Modern antipsychotic drugs: A critical overview. Canadian Medical Association Journal, 172, 1703–1711. doi: https://doi.org/10.1503/cmaj.1041064
- Gerra, G., Di Petta, G., D’amore, A., Iannotta, P., Bardicchia, F., Falorni, F., Zaimovic, A. (2007). Combination of olanzapine with opioid-agonists in the treatment of heroin-addicted patients affected by comorbid schizophrenia spectrum disorders. Clinical Nueropharmacology, 30, 127–135. doi: https://doi.org/10.1097/wnf.0b013e31803354f6
- Ghitza, U., Epstein, D., & Preston, K. (2007). Nonreporting of cannabis use: Predictors and relationship to treatment outcomes in methadone maintained patients. Addictive Behaviors, 32, 938–949. doi: https://doi.org/10.1016/j.addbeh.2006.06.034
- Ghodse, H., Corkery, J., Claridge, H., Goodair, C., & Schifano, F. (2013). Drug-related deaths in the UK: Annual report 2012. London: International Centre for Drug Policy. Retrieved from: http://www.sgul.ac.uk/media/np-sad2012/np-sad-13th-annual-report-2012finalversionfeb28thmastercopy.pdf [Accessed 4th March 2014]
- Gobbart, S. (2013). ‘Changing habits’: an evaluation of a dual diagnosis focused, integrated multimodal, psychosocial education and skill building group programme delivered in a community-based setting. Mental Health and Substance Use, 6, 29–46. doi: https://doi.org/10.1080/17523281.2012.660980
- Gonzalez, G., Miozzo, R., & Ziedonis, D. (2010). Substance abuse disorders. In Rothschild, A. (Ed.), The evidence-based guide to antipsychotic medication (pp. 125–144). Arlington, VA: American Psychiatric Publishing
- Gowing, L., Ali, R., & White, J. (2009). Buprenorphine is more effective than clonidine or iofexidine, and may have advantages over methadone, for the management of opioid withdrawal. Cochrane Review. Drugs and Alcohol Group. Retreived from: http://cda.cochrane.org
- Green, A. (2006). Treatment of schizophrenia and comorbid substance abuse: Pharmacologic approaches. The Journal of Clinical Psychiatry, 67, 31–35
- Green, A., Drake, R., Brunette, M., & Noordsy, D. (2007). Schizophrenia and co-occurring substance use disorder. American Journal of Psychiatry, 164, 402–408. doi: https://doi.org/10.1176/appi.ajp.164.3.402
- Grupp, K. (2008). Women with co-occurring substance abuse disorders and PTSD: How women understand their illness. Journal of Addictions Nursing, 19, 49–54. doi: https://doi.org/10.1080/10884600802111697
- Hakkinen, M., Launianen, T., Vuori, E., & Ojanpera, I. (2012). Benzodiazepines and alcohol are associated with cases of fatal buprenorphine poisoning. European Journal of Clinical Pharmacology, 68, 301–209. doi: https://doi.org/10.1007/s00228-011-1122-4
- Halasz, I., Levy-Gigi, E., Kelemen, O., Benedek, G., & Keri, S. (2013). Neuropsychological functions and visual contrast sensitivity in schizophrenia: The potential impact of comorbid posttraumatic stress disorder (PTSD). Frontiers in Psychology, 4, 136. doi: http://dx.doi.org/10.3389/fpsyg.2013.00136
- Hedenrud, T.M., Svensson, S.A., & Wallerstedt, S.M. (2013). “Psychiatry is not a science like others” – a focus group study on psychotropic prescribing in primary care. BMC Family Practice, [online], 14, 115. doi: 10.1186/1471-2296-14-115
- Hill, D., Penson, W., & Charura, D. (2016). Working with dual diagnosis: A psychosocial perspective. Basingstoke: Palgrave
- Hilton, T. (2007). Pharmacological issues in the management of people with mental illness and problems with alcohol and illicit drug use. Criminal Behaviour and Mental Health, 17, 215–224. doi: https://doi.org/10.1002/cbm.669
- Houston, J., Murphy, J., Adamson, G., Stringer, M., & Shevlin, M. (2008). Childhood sexual abuse, early cannabis use, and psychosis: Testing an interaction model based on the National Comorbidity Survey. Schizophrenia Bulletin, 34, 580–585. doi: https://doi.org/10.1093/schbul/sbm127
- Hughes, E., Wanigaratne, S., Gournay, K., Johnson, S., Thornicroft, G., Finch, E., … Smith, N. (2008). Training in dual diagnosis interventions (the COMO Study): Randomised controlled trial. BMC Psychiatry, 8, 1–9. doi: https://doi.org/10.1186/1471-244x-8-12
- Hunt, G.E., Siegfried, N., Morley, K., Sitharthan, T., & Cleary, M. (2013). Psychosocial interventions for people with both severe mental illness and substance misuse. Schizophrenia Bulletin, 40, 18–20. doi: 10.1093/schbul/sbt160
- Jamison, R.N., Ross, E.L., Michna, E., Chen, L.Q., Holcomb, C., & Wasan, A.D. (2010). Substance misuse treatment for high risk chronic pain patients on opioid therapy: A randomized trial. Pain, 150, 390–400. doi: https://doi.org/10.1016/j.pain.2010.02.033
- Jariani, M., Saaki, M., Nazari, H., & Birjandi, M. (2010). The effect of olanzapine and sertraline on personality disorder in patients with methadone maintenance therapy. Psychiatria Danubina, 22, 544–547
- Joint Formulary Committee (JFC). (2014). British national formulary [online] (67th ed.). London: BMJ Group and Pharmaceutical Press
- Khantzian, E.J. (1985). The self-medication hypothesis of addictive disorders: Focus on heroin and cocaine dependence. American Journal of Psychiatry, 142, 1259–1264
- Khantzian, E.J. (2003). The self-medication hypothesis revisited: The dually diagnosed patient. Primary Psychiatry, 10, 47–54
- Krantz, M., Kutinsky, I., Robertson, A., & Mehler, P. (2003). Dose-related effects of methadone on QT prolongation in a series of patients with Torsade de Pointes. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 23, 802–805. doi: https://doi.org/10.1592/phco.23.6.802.32186
- Kvaternik, I., & Grebene, V. (2009). The role of social work in the field of mental health: Dual diagnoses as a challenge for social workers. European Journal of Social Work, 12, 509–521. doi: https://doi.org/10.1080/13691450902981426
- Lanier, R., Umbrecht, A., Harrison, J., Nuwayser, E., & Bigelow, G. (2008). Opiod detoxification via single 7-day application of a buprenorphine transdermal patch: An open-label evaluation. Psychopharmacology, 198, 149–158. doi: https://doi.org/10.1007/s00213-008-1105-z
- Lawrence-Jones, J. (2010). Dual diagnosis (Drug/alcohol and mental health): Service user experiences. Practice, 22, 115–131. doi: https://doi.org/10.1080/09503151003686684
- Leslie, D.L., & Rosenheck, R.A. (2002). From conventional to atypical antipsychotics and back: Dynamic processes in the diffusion of new medications. American Journal of Psychiatry, 159, 1534–1540. doi: https://doi.org/10.1176/appi.ajp.159.9.1534
- Loberg, E.-M., & Hugdahl, K. (2009). Cannabis use and cognition in schizophrenia. Frontiers in Human Neuroscience, 3, 53. doi: https://doi.org/10.3389/neuro.09.053.2009
- Lucas, C., & Martin, J. (2013). Smoking and drug interactions. Australian Prescriber, 36, 102–104. doi: https://doi.org/10.18773/austprescr.2013.037
- Lysaker, P., & LaRocco, V. (2008). The prevalence and correlates of trauma-related symptoms in schizophrenia spectrum disorder. Comprehensive Psychiatry, 49, 330–338. doi: https://doi.org/10.1016/j.comppsych.2007.12.003
- Manez, A., Munoz, C., Aleixandre, N., Garcia, M., Tudela, L., & Gomez, F. (2010). Treatment with amisupride of addicted patients to psychoactive substances and psychotic symptoms. Actas Espanolas De Psiquiatria, 38, 138–146
- Maremmani, I., Giovanni, A., Rovai, L., Pani, P., Pacini, M., Lamanna, F., … Dell’Osso, L. (2011). Do methadone and buprenorphine have the same impact on psychopathological symptoms of heroin addicts? Annals of General Psychiatry, 10, 17–24. doi: 10.1186/1744-859X-10-17
- Mattick, R., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Review. Drugs and Alcohol Group. Retrieved from: http://cda.cochrane.org
- McCance-Katz, E., Sullivan, L., & Nallani, S. (2010). Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: A review. The American Journal on Addiction, 19, 4–16. doi: https://doi.org/10.1111/j.1521-0391.2009.00005.x
- McEvoy, J., Lieberman, J., Stroup, T.S., Davis, S., Meltzer, H., Rosenheck, R., … Hsiao, J. (2006). Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal Psychiatry, 163, 600–610. doi: https://doi.org/10.1176/appi.ajp.163.4.600
- McKeown, O. 2009. Definition, recognition and assessment. In Phillips, P., McKeown, O., & Sandford, T. (Eds.), Dual diagnosis: Practice in context (pp. 3–12). Chichester: Blackwell
- Meltzer, H., & McGurk, S. (1999). The Effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin, 25, 233–255. doi: https://doi.org/10.1093/oxfordjournals.schbul.a033376
- Morgan, C., Reininghaus, U., Reichenberg, A., Frissa, S., SELCoH Study Team, Hotopf, M., Hatch, S. (2014). Adversity, cannabis use and psychotic experiences: Evidence of cumulative and synergistic effects. British Journal of Psychiatry, 204, 346–353. doi: https://doi.org/10.1192/bjp.bp.113.134452
- Morrison, A., Turkington, D., Pyle, M., Spencer, H., Brabban, A., Dunn, G., et al. (2014). Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: A single-blind randomised controlled trial. Lancet, 383, 1395–1403. doi: https://doi.org/10.1016/s0140-6736(13)62246-1
- Mueser, K., Drake, R., & Wallach, M. (1998). Dual diagnosis: A review of etiological theories. Addictive Behavior, 23, 717–734. doi: http://dx.doi.org/10.1016/S0306-4603(98)00073-2
- Najavits, L.M., Gotthardt, S., Weiss, R.D., & Epstein, M. (2004). Cognitive distortions in the dual diagnosis of PTSD and substance use disorder. Cognitive Therapy and Research, 28, 159–172. doi: https://doi.org/10.1023/b:cotr.0000021537.18501.66
- National Institute for Health and Clinical Excellence (NICE). (2007). Methadone and buprenorphine for the management of opioid dependence. London: National Institute for Health and Clinical Excellence. Retrieved from: www.nice.org.uk/nicemedia/live/11606/33833/33833.pdf [Accessed 14th May 2014]
- National Institute for Health and Clinical Excellence (NICE). (2011). Psychosis with coexisting substance misuse: Assessment and management in adults and young people. NICE clinical guideline 120. London: National Institute for Health and Clinical Excellence. Retrieved from: www.nice.org.uk/nicemedia/live/13414/53691/53691.pdf [Accessed 8th April 2014]
- Parrish, M. (2014). Social work perspectives on human behaviour (2nd ed.). Maidenhead: Open University Press
- Patel, J.K., & Deligiannidis, K. (2010). Schizophrenia and schizoaffective disorder. In Rothschild, A. (Ed.), The evidence-based guide to antipsychotic medications (pp. 5–43). Arlington, VA: American Psychiatric Publishing
- Pilgrim, J., & Drummer, O. (2013). The toxicology and comorbidities of fatal cases involving quetiapine. Forensic Science, Medicine, and Pathology, 9, 170–176. doi: https://doi.org/10.1007/s12024-012-9404-4
- Raskin, S., Katz, G., Zislin, Z., Knobler, H., & Durst, R. (2000). Clozapine and resperidone: Combination/augmentation treatment of refractory schizophrenia: A preliminary observation. Acta Psychiatrica Scandinavia, 101, 334–336. doi: https://doi.org/10.1034/j.1600-0447.2000.101004334.x
- Read, J. (2009). Psychiatric drugs: Key issues and service user perspectives. Basingstoke: Palgrave
- Reynolds, M., Mezey, G., Chapman, M., Wheeler, M., Drummond, C., & Baldacchino, A. (2005). Co-morbid post-traumatic stress disorder in a substance misusing clinical population. Drug and Alcohol Dependence, 77, 251–258. doi: https://doi.org/10.1016/j.drugalcdep.2004.08.017
- Saber-Tehrani, A.S., Bruce, R.D., & Altice, F.L. (2011). Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence. The American Journal of Drug and Alcohol Abuse, 37, 1–11. doi: https://doi.org/10.3109/00952990.2010.540279
- Sadock, B., Sadock, V., & Ruiz, P. (2015). Kaplan and Sadock’s synopsis of psychiatry (11th ed.). London: Wolters Kluwer
- Salomon, K., & Jin, A. (2013). Diathesis-stress model. In Gellman, M., Turner, J.R. (Eds.), Encyclopedia of behavioral medicine (pp. 591–592). NYC: Springer
- Scavone, J., Sterling, R., Weinstein, S., & Van Bockstaele, E. (2013). Impact of cannabis use during stabilization on methadone maintenance treatment. American Journal on Addictions, 22, 344–351. doi: https://doi.org/10.1111/j.1521-0391.2013.12044.x
- Schottenfeld, R. (2007). Agonist maintenance treatment. In: Gabbard, G.O. (Ed.), Gabbard’s treatment of psychiatric disorders (4th ed., pp. 231–236). Arlington: American Psychological Publishing
- Schulte, M., & Hser, Y.-I. (2014). Substance use and associated health conditions throughout the lifespan. Public Health Reviews, 35, 1–27
- Seldén, T., Ahlner, J., Druid, H., & Kronstrand, R. (2012). Toxicological and pathological findings in a series of buprenorphine related deaths. Possible risk factors for fatal outcome. Forensic Science International, 220, 284–290. doi: https://doi.org/10.1016/j.forsciint.2012.03.016
- Shields, L., Hunsaker, J., Corey, T., Ward, M., & Stewart, D. (2007). Methadone toxicity fatalities: A review of medical examiner cases in a large metropolitan area. Journal of Forensic Sciences, 52, 1389–1395. doi: https://doi.org/10.1111/j.1556-4029.2007.00565.x
- Smith, G., & Velleman, R. (2007). Family intervention for co-existing mental health and drug and alcohol problems. In Baker, A., & Velleman, R. (Eds.), Clinical handbook of co-existing mental health and drug and alcohol problems (pp. 74–95). Hove: Routledge
- Sun, A.-P. (2012). Helping homeless individuals with co-occurring disorders: The four components. Social Work, 57, 23–37. doi: https://doi.org/10.1093/sw/swr008
- Taylor, D., & Paton, C. (2015). The Maudsley prescribing guidelines (11th ed.). London: Taylor & Francis
- Tiihonen, J., Lonnqvist, J., Wahlbeck, K., Klaukka, K., Nislavern, L., Tanskanen, A., & Haukla, J. (2009). 11-year follow-up of mortality in patients with schizophrenia (FIN11 study). Lancet, 374, 620–627. doi: https://doi.org/10.1016/s0140-6736(09)60742-x
- Uehlinger, C., Crettol, S., Chassot, P., Brocard, M., Koeb, L., Brawand-Amey, M., & Eap, C.B. (2007). Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients. Journal of Clinical Psychopharmacology, 27, 273–278. doi: https://doi.org/10.1097/jcp.0b013e3180592ad2
- Vazquez, M., Castillo, I., Jimenez-Lerma, J., Beldarrain, J., & Gutierrez-Fraile, M. (2009). Clinical trial on the use of olanzapine in reducing the consumption of cocaine in methadone maintenance programmes. Heroin Addiction and Related Clinical Problems, 11, 21–30
- Vieweg, W., Lipps, W., & Fernandez, A. (2005). Opioids and methadone equivalents for clinicians. Journal of Clinical Psychiatry, 7, 86–88. doi: https://doi.org/10.4088/pcc.v07n0301
- Velligan, D., Lam, Y.-W., Glahn, D., Barrett, J., Maples, N., Ereschefsky, L., & Miller, A. (2006). Defining and assessing adherence to oral antipsychotics: A review of the literature. Schizophrenia Bulletin, 32, 724–742. doi: https://doi.org/10.1093/schbul/sbj075
- Weaver, T., Madden, P., Charles, V., Stimson, G., Renton, A., Tyrer, P., … Ford, C. (2003). Comorbidity of substance misuse and mental illness in community mental health and substance misuse services. The British Journal of Psychiatry, 183, 304–313. doi: https://doi.org/10.1192/bjp.183.4.304
- Weiden, P.J., Preskorn, S.H., Fahnestock, P.A., Carpenter, D., Ross, R., & Docherty, J.P. (2007). Translating the psychopharmacology of antipsychotics to individualized treatment for severe mental illness: A Roadmap. Journal of Clinical Psychiatry, 68, 1–48
- Weizman, T., Gelkopf, M., Melamed, Y., Adelson, M., & Bleich, A. (2003). Treatment of benzodiazepine dependence in methadone maintenance treatment patients: A comparison of two therapeutic modalities and the role of psychiatric comorbidity. Australian and New Zealand Journal of Psychiatry, 37, 458–463. doi: https://doi.org/10.1046/j.1440-1614.2003.01211.x
- Woodward, N.D., Purdon, S.E., Meltzer, H.Y., & Zald, D.H. (2005). A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. The International Journal of Neuropsychopharmacology, 8, 457–472. doi: 10.1017/s146114570500516x
- Yokell, M.A., Zaller, N.D., Green, T.C., & D Rich, J.D. (2011). Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: An international review. Current Drug Abuse Reviews, 4, 28–41. doi: https://doi.org/10.2174/1874473711104010028
- Zuckerman, M. (1999). Vulnerability to psychopathology: A biosocial model. Washington, DC: APA, xv, 535 pp. doi: http://dx.doi.org/10.1037/10316-001